{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:42:36Z","timestamp":1792226556066,"version":"4.4.0"},"reference-count":16,"publisher":"Baycinar Tibbi Yayincilik","issue":"4","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Agri"],"accepted":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    This study aims to evaluate the association between escitalopram prophylaxis and pain intensity in patients with tension-type headache.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and Methods:<\/jats:bold>\n                    This retrospective, comparative cohort study included a total of 503 patients between July 1\n                    <jats:sup>st<\/jats:sup>\n                    , 2022 and October 1\n                    <jats:sup>st<\/jats:sup>\n                    , 2022. The patients were divided into two groups according to their treatment approach. The first group (Group 1, n = 300) consisted of patients who initiated escitalopram prophylaxis. The second group (Group 2, n = 203) consisted of patients who did not receive prophylactic treatment and were monitored with symptomatic treatment. Pain intensity was assessed using the Visual Analog Scale (VAS) at baseline and after approximately three months. Between-group changes were compared, and follow-up VAS scores were evaluated using regression models adjusted for baseline VAS, age and sex. The Headache Screening Questionnaire (HSQ) findings were considered exploratory.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Of a total of 503 patients, 159 were male and 344 were female with a mean age of 33.00 \u00b1 3.44 (range, 22 to 46) years. The groups were similar in age and sex distribution, although baseline VAS scores were higher in the escitalopram group. The mean VAS scores decreased from 5.06 \u00b1 1.23 to 4.55 \u00b1 1.17 in the escitalopram group and increased from 4.68 \u00b1 1.40 to 4.92 \u00b1 1.41 in the symptomatic treatment group. The difference in change between groups was significant. Escitalopram use remained associated with lower follow-up VAS scores after adjustment for baseline VAS, age and sex. The HSQ findings were exploratory and were not interpreted as confirmatory evidence of treatment efficacy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Escitalopram prophylaxis was associated with lower pain intensity after approximately three months. As treatment allocation was non-randomized and baseline pain severity differed between groups, the findings should be interpreted cautiously. Escitalopram warrants further investigation in patients who cannot tolerate or are unsuitable for first-line prophylactic treatments.\n                  <\/jats:p>","DOI":"10.5606\/agri.2026.170","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:31:27Z","timestamp":1792225887000},"page":"264-271","source":"Crossref","is-referenced-by-count":0,"title":["Association of escitalopram prophylaxis with pain intensity in tension-type headache: A retrospective, comparative cohort study"],"prefix":"10.5606","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3511-090X","authenticated-orcid":false,"given":"Ahmet Burak","family":"Elbeyli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-184X","authenticated-orcid":false,"given":"Ali Zeynal Abidin","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3570","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache--report of an EFNS task force. Eur J Neurol 2010;17:1318-25.","DOI":"10.1111\/j.1468-1331.2010.03070.x"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, et al. Tricyclic antidepressants and headaches: Systematic review and meta-analysis. BMJ 2010;341:c5222. doi: 10.1136\/bmj.c5222.","DOI":"10.1136\/bmj.c5222"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Holroyd KA, O\u2019Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: A randomized controlled trial. JAMA 2001;285:2208-15. doi: 10.1001\/jama.285.17.2208.","DOI":"10.1001\/jama.285.17.2208"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"G\u00f6bel H, Hamouz V, Hansen C, Heininger K, Hirsch S, Lindner V, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not  alter pericranial muscle activity readings. Pain 1994;59:241-9. doi: 10.1016\/0304-3959(94)90077-9.","DOI":"10.1016\/0304-3959(94)90077-9"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996;61:285-90. doi: 10.1136\/jnnp.61.3.285.","DOI":"10.1136\/jnnp.61.3.285"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) for the prevention of tension-type headache in adults. Cochrane Database Syst Rev 2015;2015:CD011681. doi: 10.1002\/14651858.CD011681.","DOI":"10.1002\/14651858.CD011681"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007;27:315-24. doi: 10.1111\/j.1468-2982.2007.01300.x.","DOI":"10.1111\/j.1468-2982.2007.01300.x"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care 2014;8:143- 51. doi: 10.1097\/SPC.0000000000000055.","DOI":"10.1097\/SPC.0000000000000055"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Bardoni R. Serotonergic modulation of nociceptive circuits in spinal cord dorsal Horn. Curr Neuropharmacol 2019;17:1133-45. doi: 10.217 4\/1570159X17666191001123900.","DOI":"10.2174\/1570159X17666191001123900"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 2009;32:254-8. doi: 10.1097\/WNF.0b013e3181a8c84f.","DOI":"10.1097\/WNF.0b013e3181a8c84f"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003;167:353-62. doi: 10.1007\/s00213- 002-1364-z.","DOI":"10.1007\/s00213-002-1364-z"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L. PET measurement of serotonin transporter occupancy: A comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 2007;10:777-85. doi: 10.1017\/S1461145706007486.","DOI":"10.1017\/S1461145706007486"},{"key":"ref-13","unstructured":"Turkish Neurological Society. T\u0130TCK Ek4 n\u00f6roloji endikasyon d\u0131\u015f\u0131 ba\u015fvurusu yay\u0131nland\u0131. Published February 17, 2023. Available from: https:\/\/noroloji.org.tr\/haber\/1484\/titck-ek4-noroloji-endikasyon-disibasvurusu-yayinlandi. [Accessed: July 26, 2026]."},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211. doi: 10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63:S240-52. doi: 10.1002\/acr.20543.","DOI":"10.1002\/acr.20543"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"van der Meer HA, Visscher CM, Engelbert RHH, Mulleners WM, Nijhuis-van der Sanden MWG, Speksnijder CM. Development and psychometric validation of the headache screening questionnaire - Dutch Version. Musculoskelet Sci Pract 2017;31:52-61. doi: 10.1016\/j. msksp.2017.07.001.","DOI":"10.1016\/j.msksp.2017.07.001"}],"container-title":["A\u011fr\u0131 - The Journal of The Turkish Society of Algology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/agridergisi.com\/tam-metin-pdf\/999\/eng","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agridergisi.com\/tam-metin-pdf\/999\/eng","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:31:51Z","timestamp":1792225911000},"score":1,"resource":{"primary":{"URL":"https:\/\/agridergisi.com\/doi\/10.5606\/agri.2026.170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.5606\/agri.2026.170","relation":{},"ISSN":["1300-0012","2458-9446"],"issn-type":[{"value":"1300-0012","type":"print"},{"value":"2458-9446","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]}}}